Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

June 2024

A disease-associated gene desert directs macrophage inflammation through ETS2

Nature 2024 doi: 10.1038/s41586-024-07501-1 Epub ahead of print

Haag LM,

Papa I,

Zhang Q,

Zhang T,

Wood CS,

New FN,

Hall A,

Jiang L,

Saruhan-Direskeneli G,

Green M,

Nye E,

Stankey, et al. used functional genomics to show that the ETS2 gene is a central regulator of human inflammatory macrophages. They also found that ETS2 was disrupted by JAK inhibitors and MEK inhibitors, with multiple MEK inhibitors being shown to downregulate ETS2-target genes.

Keywords:

JAK,
MOA

December 2022

バリシチニブ治療中の関節リウマチ患者におけるVTE, MACE, 重篤感染症のTNFi治療と比較した評価: レジストリとクレームデータベースを使用した複数データベース試験

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00505-1

Bower H,

Song Y,

Bosan R,

Zhu B,

Mai X,

Deberdt W; B023 Study Consortium

Salinas, et al. evaluate baricitinib safety with respect to VTE, MACE, and serious infection relative to TNFi in patients with RA, in routine care and observe an increased risk of VTE in patients taking baricitinib, compared to TNFi.